Breaking News

Lloyds Reaches $370 Million Settlement With Regulators Over Libor
Tweet TWEET

Evotec Extends Drug Discovery Alliance With Genentech

Evotec Extends Drug Discovery Alliance With Genentech

HAMBURG, Germany, April 22, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(TecDAX) (ISIN:DE0005664809) today announced that it has extended its drug
discovery alliance with Genentech, a member of the Roche Group (SIX:RO) (ROG)
(OTCQX:RHHBY), for three additional years.

The collaboration was initiated in May 2010 and this extension further
validates Evotec's technology platform and broad expertise in drug discovery.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are
delighted and proud that Genentech has decided to extend the current
agreement. Both sets of scientists have collaborated very closely over the
past few years and this extension is validation of the value we bring to
Genentech's discovery programmes."

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing the
highest quality stand-alone and integrated drug discovery solutions, covering
all activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise
in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances
with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition,
the Company has existing development partnerships and product candidates both
in clinical and pre-clinical development. These include partnerships with
Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes,
with Janssen Pharmaceuticals in the field of depression and with Roche in the
field of Alzheimer's disease. For additional information please go to
www.evotec.com.

FORWARD LOOKING STATEMENTS — Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: Dr. Werner Lanthaler
         Chief Executive Officer
         +49.(0)40.560 81-242
         +49.(0)40.560 81-333 Fax
         werner.lanthaler@evotec.com
        
         Evotec AG
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Germany)
        
         Gabriele Hansen
         Head of Corporate Communications
         +49.(0)40.560 81-255
         +49.(0)40.560 81-222 Fax
         gabriele.hansen@evotec.com
        
         Evotec AG
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Germany)